My watch list
my.bionity.com  

my.bionity.com

With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Certolizumab pegol



 The introduction to this article provides insufficient context for those unfamiliar with the subject.
Please help improve the article with a good introductory style.

Certolizumab pegol (CDP870) (proposed tradename Cimzia) is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.

It is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [2]

Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.

In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.

References

  1. ^ Sandborn WJ, Feagan BG, Stoinov S, et al (2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228-38. doi:10.1056/NEJMoa067594. PMID 17634458.
  2. ^ Kaushik VV, Moots RJ (2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy 5 (4): 601-6. doi:10.1517/14712598.5.4.601. PMID 15934837.
v • d • e
Humanized monoclonal antibodies
CancerAlemtuzumab, Apolizumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab
ImmunosuppressionAselizumab, Atlizumab, Cedelizumab, Daclizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab
Viral infectionsFelvizumab, Palivizumab, PRO 140
otherBapineuzumab, Certolizumab pegol, Eculizumab, Motavizumab, Natalizumab, Ocrelizumab, Omalizumab, Ranibizumab, Tadocizumab, Tefibazumab, Tucotuzumab celmoleukin, Urtoxazumab
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Certolizumab_pegol". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE